CareFusion Corp.’s (NYSE:CFN) first-quarter profits are up 76 percent from 2011 numbers for the three months ended Sept. 30, in spite of a recall of its Avea ventilators.
CareFusion posted profits of $67 million, or 30 cents per share, on a sales of $844 million for the quarter – a top-line increase of 4.1 percent compared with $811 million during the same period last year. But Q1 2011 profits were only $38 million, or 17 cents per share.
The San Diego, Calif.-based company chalked up the great bottom line to its dispensing technologies and infusion systems businesses and a lower tax rate.
Sign up to get our free newsletters delivered straight to your inbox
"During the quarter, we transitioned from our stand-up phase to our foundation building stage, and made progress in our efforts to simplify how we do business and invest in areas to help expand margins and accelerate our top line growth," said CareFusion chairman & CEO Kieran Galahue, in prepared remarks.
The company might not be so lucky in their second quarter. Mid-October, the FDA slapped CareFusion Corp.’s EnVe ventilator recall with Class I status over concerns that glitches in the device may lead to serious neurological injury or death from insufficient ventilation.
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Biolase’s Q3 profits in the red despite sales rise of 110 percent
Third-quarter sales for Biolase (NASDAQ:BLTI) surged 110 percent in the three months ended Sept. 30. The Irvine, Calif.-based dental laser company posted a 110 percent increase in sales to $13 million, compared to $6.2 million during the same period last year.
Company profits were still in the red, but down 65 percent at a loss of $953,000, or 3 cents per diluted share, compared to a loss of $2.7 million, or 10 cents per diluted share in Q3 of 2010.
Read more
Delcath loses $8.3M in Q3
Delcath Systems (NASDAQ:DCTH) saw a loss of $8.3 million in the three months ended September 30. The New York-based oncological device company posted a 12.8 percent difference in profit loss to $8.3 million, or 18 cents per diluted share, compared to $9.5 million, or 24 cents per diluted share in Q3 of 2010.
Read more
HOLX swings into black at the close of its fiscal year
Hologic (NSDQ:HOLX) saw a 9 percent increase in the three months ended Sept. 24. The Bedford, Mass.-based diagnostics developer posted a 9 percent increase in sales to $467 million, compared to $428 million during the same period last year.
Company profits landed in the black with a gain of $27 million, or 10 cents per diluted share, compared to a loss of $136 million, or 53 cents per diluted share in Q4 of 2010.
The diagnostics developer saw a 6.5 percent increase in sales for the whole of its fiscal year to $1.79 billion, compared to $1.68 billion during the end of the 2010 fiscal year. The company’s profits were way up with a gain of $157 million, or 59 cents per diluted share, compared to a loss of $62.8 million or 24 cents per diluted share at the close of the 2010 fiscal year.
Read more
Mindray’s numbers steadily up in Q2
Mindray Medical International (NYSE:MR) saw a rise across the board in the three months ended June 30. The global medical device company company posted a 21.3 percent increase in sales to $217 million, compared to $179 million during the same period last year.
Company profits rose 5.9 percent to $45 million, or 37 cents per diluted share, compared to $42 million, or 36 cents per diluted share in Q2 of 2010.
Read more
pSivida sales up 248 percent in Q1
pSivida Corp. (NASDAQ:PSDV) saw a 248 percent jump in sales in the three months ended Sept. 30. The Watertown, Mass.-based drug delivery device maker posted a 248 percent increase in sales to $1.6 million, compared to $476,000 during the same period last year.
Company losses decreased 21.9 percent to $2.4 million, or 12 cents per diluted share, compared to $3.1 million, or 17 cents per diluted share in Q1 of last year.
Read more
Q3 numbers leave Stereotaxis in the red
Stereotaxis Inc. (NASDAQ:STXS) saw a 38 percent decrease in profits in the three months ended Sept. 30. The St. Louis-based cardiovascular device company posted a 38.4 percent decrease in sales to $8.5 million, compared to $13.9 million during the same period last year.
Company losses increased 41.4 percent to $7.3 million, or 13 cents per diluted share, compared to $5.1 million, or 10 cents per diluted share in Q3 of 2010.
Read more
ULGX profits down by 95 percent in Q1
Urologix Inc. (NASDAQ:ULGX) saw a 95.5 percent decrease in profits in the three months ended Sept. 30. The Minneapolis, Minn.-based medical device company posted a 6.3 percent decrease in sales to $3.1 million, compared to $3.3 million during the same period last year.
Company losses increased 95.5 percent to $1.3 million, or 9 cents per diluted share, compared to $708,000, or 5 cents per diluted share in Q1 of 2010.
Read more
Vision-Sciences Q2 sales up 73 percent
Orangeburg, N.Y.-based Vision-Sciences Inc. (NASDAQ:VSCI) saw its sales rise 73 percent in the three months ended Sept. 30. The medical device company posted a 73.1 percent increase in sales to $4 million, compared to $2.3 million during the same period last year.
Company losses decreased 2 percent to $2.9 million, or 7 cents per diluted share, compared to $3.01 million, or 8 cents per diluted share in Q2 of 2010.
Read more
